Inactive Ingredient Search for Approved Drug Products

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with T

Quarter Inactive Ingredient Route of Administration Dosage Form Maximum Potency per unit dose Maximum Daily Exposure Status
8961 Q3 2021 TALC ORAL TABLET, MULTILAYER, EXTENDED RELEASE 18 mg Correction
8961 Q4 2021 TALC ORAL TABLET, MULTILAYER, EXTENDED RELEASE 9.00 mg Correction
8952 Q3 2021 TALC ORAL TABLET, CHEWABLE, EXTENDED RELEASE 12.00 mg MDE Replacement
8952 Q4 2021 TALC ORAL TABLET, CHEWABLE, EXTENDED RELEASE 18 mg MDE Replacement
8959 Q3 2021 TALC ORAL TABLET, FILM COATED, EXTENDED RELEASE 30.00 mg MDE Replacement
8959 Q4 2021 TALC ORAL TABLET, FILM COATED, EXTENDED RELEASE 60 mg MDE Replacement
8986 Q3 2021 TARTARIC ACID ORAL TABLET, FOR SUSPENSION 7.00 mg MDE Replacement
8986 Q4 2021 TARTARIC ACID ORAL TABLET, FOR SUSPENSION 28 mg MDE Replacement
9009 Q3 2021 TERT-BUTYLHYDROQUINONE VAGINAL CREAM 0.02 %w/w MDE Replacement
9009 Q4 2021 TERT-BUTYLHYDROQUINONE VAGINAL CREAM 0.8 mg MDE Replacement
9033 Q3 2021 TITANIUM DIOXIDE BUCCAL FILM, SOLUBLE 2.78 mg MDE Replacement
9033 Q4 2021 TITANIUM DIOXIDE BUCCAL FILM, SOLUBLE 2.78 mg MDE Replacement
9051 Q3 2021 TITANIUM DIOXIDE ORAL SUSPENSION 75 mg Correction
9051 Q4 2021 TITANIUM DIOXIDE ORAL SUSPENSION 80 mg Correction
9057 Q3 2021 TITANIUM DIOXIDE ORAL TABLET, FILM COATED 24.23 mg MDE Replacement
9057 Q4 2021 TITANIUM DIOXIDE ORAL TABLET, FILM COATED 36 mg MDE Replacement
9099 Q3 2021 TRIACETIN ORAL TABLET, CHEWABLE, EXTENDED RELEASE 1.36 mg MDE Replacement
9099 Q4 2021 TRIACETIN ORAL TABLET, CHEWABLE, EXTENDED RELEASE 2.04 mg MDE Replacement
9136 Q3 2021 TRIETHYL CITRATE ORAL GRANULE, FOR SUSPENSION 6.94 mg MDE Replacement
9136 Q4 2021 TRIETHYL CITRATE ORAL GRANULE, FOR SUSPENSION 6.94 mg MDE Replacement
9158 Q3 2021 TRISODIUM CITRATE DIHYDRATE INTRACARDIAC INJECTION 0.21 %w/v MDE Replacement
9158 Q4 2021 TRISODIUM CITRATE DIHYDRATE INTRACARDIAC INJECTION 18.63 mg MDE Replacement
9191 Q3 2021 TRISODIUM CITRATE DIHYDRATE SUBCUTANEOUS INJECTION 0.63 %w/v MDE Replacement
9191 Q4 2021 TRISODIUM CITRATE DIHYDRATE SUBCUTANEOUS INJECTION 18.63 mg MDE Replacement
9215 Q3 2021 TROLAMINE TOPICAL GEL, METERED 1.00 %w/w MDE Replacement
9215 Q4 2021 TROLAMINE TOPICAL GEL, METERED 19.25 mg MDE Replacement
9245 Q3 2021 TROMETHAMINE ORAL CAPSULE 15.00 mg MDE Replacement
9245 Q4 2021 TROMETHAMINE ORAL CAPSULE 30 mg MDE Replacement
9204 Q4 2021 TRISODIUM HEDTA TOPICAL SPONGE 0.01 %w/w Deletion
9247 Q4 2021 TROMETHAMINE ORAL SOLUTION/ DROPS 7.60 mg/ 1.00 ml Deletion

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: September 30, 2021
Database Last Updated: October 21, 2021

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English